MYRIAD GENETICS INC (MYGN) earnings date
Feb 23, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 45% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 36 days, typically, give or take 10 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Wed, Nov 4, 2026 | after close | 35 | 8-K |
| Q2 FY2026 | Thu, Jul 30, 2026 | after close | 30 | 8-K |
| Q1 FY2026 | Tue, May 5, 2026 | after close | 35 | 8-K |
| Q4 FY2025 | Mon, Feb 23, 2026 | after close | 54 | 8-K |
| Q3 FY2025 | Mon, Nov 3, 2025 | after close | 34 | 8-K |
| Q2 FY2025 | Tue, Aug 5, 2025 | after close | 36 | 8-K |
| Q1 FY2025 | Tue, May 6, 2025 | after close | 36 | 8-K |
| Q4 FY2024 | Mon, Feb 24, 2025 | after close | 55 | 8-K |
What they guided beta
| Q3 FY2026 | "Document Exhibit 99.1 Myriad Genetics Reports Third Quarter 2026 Financial Results; Raises Mid-Point of Full-Year 2026 Revenue Guidance Following Solid Execution Definitive Agreement to Sell Prenatal Health Business to Support Strategic Growth Initiatives Highl ights" exhibit |
| Q3 FY2026 | "Raises mid-point of full-year 2026 revenue guidance to reflect third quarter 2026 results and current business trends for the remainder of 2026." exhibit |
| Q3 FY2026 | "SALT LAKE CITY, November 4, 2026 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced financial results for its third quarter ended September 30, 2026, and raised the mid-point of revenue guidance for the full-year 2026. 1 “We have made meaningful progress on our path to accelerate profitable growth and strengthen the company’s financial profile." exhibit |
| Q3 FY2026 | "Lastly, we are increasing the mid-point of our full-year 2026 revenue guidance modestly, as we balance the positive third quarter 2026 performance with the timing of the sale of the Prenatal Health business, which is expected to close by early 2027." Financial and Operational Highlights" exhibit |
| Q3 FY2026 | "A Cancer Care Continuum and Mental Health volume and revenue subtotal is presented to provide additional information regarding the revenue of the businesses expected to remain with the Company following completion of the sale, which is expected to close by early 2027." exhibit |
| Q2 FY2026 | "Revised 2026 financial guidance to reflect second quarter results and updated assumptions for business trends in the second half of 2026." exhibit |
| Q2 FY2026 | "SALT LAKE CITY, July 30, 2026 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced financial results for its second quarter ended June 30, 2026, new initiatives focused on driving increased efficiency, productivity and scalability, and revised financial guidance for the full-year 2026." exhibit |
| Q2 FY2026 | "While we are revising our full-year 2026 financial guidance due to lower Prenatal Health test volumes and more conservative assumptions regarding average revenue per test, we remain optimistic about our 2027 financial profile as we execute on multiple initiatives." Financial and Operational Highlights" exhibit |
| Q2 FY2026 | "Second quarter 2026 revenue decreased 3% year-over-year reflecting 4% year-over-year GeneSight volume growth offset by a 6% year-over-year decline in average revenue per test, which reflects a write-off of aged receivables in the quarter. 4 Financial Guidance Myriad Genetics does not provide forward-looking guidance in accordance with accounting principles generally accepted in the United States (GAAP) for the measures on which it provides forward-looking non-GAAP guidance as the company is unable to provide a quantitative reconciliation of forward-looking non-GAAP measures to the most directl" exhibit |
| Q2 FY2026 | "Below is a table summarizing Myriad Genetics' full-year 2026 financial guidance*: (in millions, except percentages) 2026 Guidance FY 2026 Comments Revenue $770 - $790 Revised the full-year 2026 revenue range lower, reflecting Q2 results and current business trends." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/MYGN
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/MYGN
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/MYGN/"><img src="https://veritasdata.dev/embed/MYGN.svg" alt="MYGN earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/MYGN/)
Script
<script async src="https://veritasdata.dev/embed/MYGN.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/MYGN"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.